Vistakon launches professional development group

Article

Vistakon has created a new professional development group that combines its professional affairs, ODLean consulting program, and optometry school educational efforts into one department.

Jacksonville, FL-Vistakon, a division of Johnson & Johnson Vision Care Inc., has created a new professional development group that combines its professional affairs, ODLean consulting program, and optometry school educational efforts into one department.
 

  • Damian May, PharmD, MBA, has been appointed senior director, Strategy & Professional Development, responsible for working with the new organization to set the vision, strategy and roadmap for the Group to meet the changing demands of the optometric marketplace.

  • Dick Wallingford, OD, has been named senior director, Professional Affairs. In this expanded role, Dr. Wallingford will continue to lead the company’s professional affairs activities with associations and eye care practitioners, as well as oversee management of its Optometry School programs.

  • W. Lee Ball, OD, FAAO, will continue to work with Dr. Wallingford to support these efforts.
     

Said Dave Brown, Vistakon president: “Under Damian and Dick’s proven leadership, we believe we are well poised to help current and future optometrists prepare for and readily adapt to a complex and fast-changing healthcare environment.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.